SCHEMBL30584882

SCHEMBL30584882

O=C(NCCCN1CCC(Cc2ccccn2)CC1)N1CCN(c2nc(-c3ccc(F)cc3)no2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ HTT P42858 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ USP2 O75604 1/20 0.45
▸ TUBB4A P04350 1/20 0.44
▸ TUBB P07437 1/20 0.44
▸ TUBA3C P0DPH7 1/20 0.44
▸ TUBA1B P68363 1/20 0.44
▸ TUBA4A P68366 1/20 0.44
▸ TUBB4B P68371 1/20 0.44
▸ TUBB3 Q13509 1/20 0.44
▸ TUBB2A Q13885 1/20 0.44
▸ TUBB8 Q3ZCM7 1/20 0.44
▸ TUBA3E Q6PEY2 1/20 0.44
▸ TUBA1A Q71U36 1/20 0.44
▸ TUBA1C Q9BQE3 1/20 0.44
▸ TUBB6 Q9BUF5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31546341 0.92 EPHX2 (0.49) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL30584727 0.92 LMNA (0.47) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL30584895 0.92 LMNA (0.45) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL31667543 0.90 LMNA (0.58) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL31546447 0.90 CCR3 (0.46) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL30584775 0.90 LMNA (0.49) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL30584805 0.90 LMNA (0.48) LMNASMN1; SMN2HTTTSHRALDH1A1
Formic Acid SCHEMBL31546410 0.88 LMNA (0.56) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL25434754 0.80 MEN1 (0.56) LMNASMN1; SMN2HTTTSHRALDH1A1
SCHEMBL25433518 0.80 MEN1 (0.56) LMNASMN1; SMN2HTTTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP claimed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 LMNA 1344/4885SMN1; SMN2 3115/4885HTT 2290/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 LMNA 1344/4885SMN1; SMN2 3115/4885HTT 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback